Controlling the cost of innovative cancer therapeutics

Nature Reviews Clinical Oncology

Volumn 6, Issue 9, 2009, Pages 550-552

  Malik, Nafees N ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; GENERIC DRUG; MONOCLONAL ANTIBODY; RITUXIMAB; TRASTUZUMAB;

ARTICLE; COST BENEFIT ANALYSIS; COST CONTROL; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; GOVERNMENT; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; NEOPLASM; PHARMACEUTICAL CARE; PRIORITY JOURNAL; REIMBURSEMENT;

ANTINEOPLASTIC AGENTS; COST CONTROL; COSTS AND COST ANALYSIS; DRUG COSTS; DRUG DISCOVERY; HUMANS; NEOPLASMS;

EID: 70450195261     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.113     Document Type: Article

References (25)

1. Kolata, G. & Pollack, A. Costly Cancer Drug Offers Hope, but Also a Dilemma. New York Times (July 6 2008) [online], http://www.nytimes.com/2008/07/06/health/06avastin.html?ex= 1373083200&en=6e4927b1af312159&ei=5124&partner= permalink&exprod=permalink (2008).
2. American Cancer Society. Cancer Facts & Figures 2007. American Cancer Society [online], http://www.cancer.org/downloads/STT/ CAFF2007PWSecured.pdf (2007).
3. Chao, E. L. & Hall, K. National Compensation Survey: Occupational Earnings in the United States, 2007. Bureau of Labor Statistics [online], http://www.bls.gov/ncs/ncswage2007.htm#Wage_tables (2008).
4. DiMasi, J. A. & Grabowski, H. G. The cost of biopharmaceutical R&D: is biotech different? Manage. Decis. Econ. 28, 469-479 (2007).
5. Rucker, N. L. Biologics in Perspective: Expanded Clinical Options amid Greater Cost Scrutiny. AARP [online], http://www.aarp.org/research/ health/drugs/fs136_biologics.html (2007).
6. IMS Health. 2007 Top Therapeutic Classes by U. S. Sales. IMS Health [online], http://www.imshealth.com/deployedfiles/ imshealth/Global/Content/Document/Top-Line%20Industry%20Data/ 2007%20Top%20Therapeutic%20Classes%20by%20Sales.pdf (2008).
7. IMS Health. Intelligence.360 - Global Pharmaceutical Perspectives 2007. IMS Health [online], http://www.imshealth.com/portal/site/ imshealth/menuitem.c96f97d74b76899 c33a004f09418c22a/?vgnextoid= b04e51dd68585110VgnVCM10000071812ca2RCRD&vgnextfmt=default (2008).
8. American Cancer Association. Monoclonal Antibodies. American Cancer Association [online], http://www.cancer.org/docroot/ETO/content/ ETO_1_4X_Monoclonal_Antibody_Therapy_Passive_Immunotherapy.asp?sitearea= ETO (2008).
9. La Merie Business Intelligence. R&D Pipeline News: Top 20 Biologics. La Merie [online], http://www.pipelinereview.com/ free-downloads/top_20_biologics_2007_rd_pipeline_news.pdf (2008).
10. Giaccotto, C., Santerre, R. E. & Vernon J. A. Drug Prices and Research and Development Investment Behavior in the Pharmaceutical Industry. J. Law. Econ. 48, 195-214 (2005).
11. U.S. Department of Commerce. Pharmaceutical Price Controls in OECD Countries: Implications for U.S. Consumers, Pricing, Research and Development, and Innovation. International Trade Administration [online], http://www.ita.doc.gov/td/health/DrugPricingStudy.pdf (2004).
12. Generic Pharmaceutical Association. About Generics. Generic Pharmaceutical Association [online], http://www.gphaonline.org/ about-gpha/about-generics (2009).
13. Congressional Budget Office. S. 1695 Biologics Price Competition and Innovation Act of 2007. Congressional Budget Office [online], http://www.cbo.gov/ftpdocs/94xx/doc9496/s1695.pdf (2008).
14. Danzon, P. M., Epstein, A. & Nicholson, S. Mergers and Acquisitions in the Pharmaceutical and Biotech Industries. Manage. Decis. Econ. 28, 307-328 (2007).
15. Generic Pharmaceutical Association. Biogenerics. Generic Pharmaceutical Association [online], http://www.gphaonline.org/ issues/biogenerics (2009).
16. Biotechnology Industrial Organization. New Bipartisan, Consensus Bill points to right path to Biosimilars. Biotechnology Industrial Organization [online], http://bio.org/news/pressreleases/ newsitem.asp?id=2009_0317_03 (2009).
17. Pharmaceutical Research and Manufacturers of America. PhRMA Statement on Rep. Eshoo's Follow-on Biologics Bill. Pharmaceutical Research and Manufacturers of America [online], http://www.phrma.org/news_room/ press_releases/phrma_statement_on_rep._eshoo%92s_follow- on_biologics_bill/ (2009).
18. Biotechnology Industry Organization. How has Europe Approached Biosimilars? Biotechnology Industry Organization [online], http://bio.org/healthcare/followonbkg/europe.asp (2009).
19. National Institute for Health and Clinical Excellence. Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appraisal consultation document. National Institute for Health and Clinical Excellence [online], http://www.nice.org.uk/guidance/ index.jsp?action=article&o=41473 (2008).
20. National Institute for Health and Clinical Excellence. Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma. National Institute for Health and Clinical Excellence [online], http://www.nice.org.uk/Guidance/TA169 (2009).
21. HHS.GOV/Recovery. United States Department of Health and Human Services [online], http://www.hhs.gov/recovery/programs/cer/ index.html (2009).
22. Bach, P. Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs. N. Engl. J. Med. 360, 626-633 (2009).
23. National Institute for Health and Clinical Excellence. Press Release. NICE guidance on bortezomib (Velcade) is a win-win solution for multiple myeloma patients and the NHS. National Institute for Health and Clinical Excellence [online], http://www.nice.org.uk/media/EB7/ 14/2007056Bortezomibformultiplemyeloma_APPv2.pdf (2007).
24. National Institute for Health and Clinical Excellence. Health and Clinical Excellence: The NICE Bulletin for Parliamentarians. National Institute for Health and Clinical Excellence [online], http://www.nice.org.uk/niceMedia/pdf/HCENovember06.pdf (2006).
25. Gavel, S. J. The Oncology Pipeline: Maturing, Competitive, and Growing? Oncology Business Review 2008 September. IMS Health [online], http://www.imshealth.com/deployedfiles/imshealth/Global/Content/ StaticFile/The_Oncology_Pipeline.pdf (2008).